Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized

Nachiket Kamatkar, Matthew Levy, Jean M. Hebert

Research output: Contribution to journalArticle

Abstract

There have been limited options for people who suffer from fibroblast growth factor receptor (FGFR) signaling disorders. In this study, we developed RNA aptamers specific for FGFR3 as potential therapeutic agents. Using a structured aptamer library, we performed ten rounds of SELEX (systematic evolution of ligands by exponential enrichment) against mouse FGFR3c protein. Using an engineered BaF3 cell line, one aptamer clone from round 6 of the selection inhibited FGF-dependent cell growth with a concentration at which 50% of growth is observed (IC50) of ∼260 nM and bound both mouse and human FGFR3 but not FGFR1 or FGFR2. This inhibitor of FGFR3 signaling (iR3), when dimerized using a template-driven approach, resulted in a functional activator of FGFR3 (aR3). We validated the activity and specificity of iR3 and aR3 on engineered BaF3 cell lines, mouse and human FGFR protein, and primary cultures of neuroepithelial precursor cells.

Original languageEnglish (US)
Pages (from-to)530-539
Number of pages10
JournalMolecular Therapy - Nucleic Acids
Volume17
DOIs
StatePublished - Sep 6 2019

Fingerprint

Nucleotide Aptamers
Fibroblast Growth Factor Receptors
SELEX Aptamer Technique
Neuroepithelial Cells
Cell Line
Growth
Inhibitory Concentration 50
Libraries
Proteins
Clone Cells
Therapeutics

Keywords

  • aptamer
  • drug
  • FGFR3

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized. / Kamatkar, Nachiket; Levy, Matthew; Hebert, Jean M.

In: Molecular Therapy - Nucleic Acids, Vol. 17, 06.09.2019, p. 530-539.

Research output: Contribution to journalArticle

@article{ac21ef29d17b4a8d97b53ff073aadedc,
title = "Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized",
abstract = "There have been limited options for people who suffer from fibroblast growth factor receptor (FGFR) signaling disorders. In this study, we developed RNA aptamers specific for FGFR3 as potential therapeutic agents. Using a structured aptamer library, we performed ten rounds of SELEX (systematic evolution of ligands by exponential enrichment) against mouse FGFR3c protein. Using an engineered BaF3 cell line, one aptamer clone from round 6 of the selection inhibited FGF-dependent cell growth with a concentration at which 50{\%} of growth is observed (IC50) of ∼260 nM and bound both mouse and human FGFR3 but not FGFR1 or FGFR2. This inhibitor of FGFR3 signaling (iR3), when dimerized using a template-driven approach, resulted in a functional activator of FGFR3 (aR3). We validated the activity and specificity of iR3 and aR3 on engineered BaF3 cell lines, mouse and human FGFR protein, and primary cultures of neuroepithelial precursor cells.",
keywords = "aptamer, drug, FGFR3",
author = "Nachiket Kamatkar and Matthew Levy and Hebert, {Jean M.}",
year = "2019",
month = "9",
day = "6",
doi = "10.1016/j.omtn.2019.06.020",
language = "English (US)",
volume = "17",
pages = "530--539",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized

AU - Kamatkar, Nachiket

AU - Levy, Matthew

AU - Hebert, Jean M.

PY - 2019/9/6

Y1 - 2019/9/6

N2 - There have been limited options for people who suffer from fibroblast growth factor receptor (FGFR) signaling disorders. In this study, we developed RNA aptamers specific for FGFR3 as potential therapeutic agents. Using a structured aptamer library, we performed ten rounds of SELEX (systematic evolution of ligands by exponential enrichment) against mouse FGFR3c protein. Using an engineered BaF3 cell line, one aptamer clone from round 6 of the selection inhibited FGF-dependent cell growth with a concentration at which 50% of growth is observed (IC50) of ∼260 nM and bound both mouse and human FGFR3 but not FGFR1 or FGFR2. This inhibitor of FGFR3 signaling (iR3), when dimerized using a template-driven approach, resulted in a functional activator of FGFR3 (aR3). We validated the activity and specificity of iR3 and aR3 on engineered BaF3 cell lines, mouse and human FGFR protein, and primary cultures of neuroepithelial precursor cells.

AB - There have been limited options for people who suffer from fibroblast growth factor receptor (FGFR) signaling disorders. In this study, we developed RNA aptamers specific for FGFR3 as potential therapeutic agents. Using a structured aptamer library, we performed ten rounds of SELEX (systematic evolution of ligands by exponential enrichment) against mouse FGFR3c protein. Using an engineered BaF3 cell line, one aptamer clone from round 6 of the selection inhibited FGF-dependent cell growth with a concentration at which 50% of growth is observed (IC50) of ∼260 nM and bound both mouse and human FGFR3 but not FGFR1 or FGFR2. This inhibitor of FGFR3 signaling (iR3), when dimerized using a template-driven approach, resulted in a functional activator of FGFR3 (aR3). We validated the activity and specificity of iR3 and aR3 on engineered BaF3 cell lines, mouse and human FGFR protein, and primary cultures of neuroepithelial precursor cells.

KW - aptamer

KW - drug

KW - FGFR3

UR - http://www.scopus.com/inward/record.url?scp=85069861712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069861712&partnerID=8YFLogxK

U2 - 10.1016/j.omtn.2019.06.020

DO - 10.1016/j.omtn.2019.06.020

M3 - Article

AN - SCOPUS:85069861712

VL - 17

SP - 530

EP - 539

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

ER -